- This collaboration, called Precision Oncology Evidence Development in Cancer Treatment, or PREDiCT, aim is to generate and assess real-world evidence, and with this data influence the development of new reimbursement pathways for precision oncology therapies
- Biomarker-informed precision oncology drugs are often indicated for rare subpopulations of cancer patients, making traditional analyses difficult – PREDiCT will encourage greater use of real-world evidence in regulatory and reimbursement decisions
to learn more.
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com
and contact us at email@example.com